梁燕现任史寨克中国区副总截,负责政府事务、市场准入和经贸头则政策研究和战略,向总裁何磊(Greg Holman)先生汇报,她于2019年加入史赛克。
在过去的20多年里,梁燕为丹纳赫、GE 医疗、辉瑞等跨国企业在中国的企业发展战略、产品市场准入战略、以及相关组织建设和人才队伍发展做出贡献,这些企业都已将中国区、亚洲区甚至全球总部落户在上海。在加入史赛克之前,她历任丹纳赫集团大中华区首任政府事务副总裁、GE医疗大中华区及亚太区首任市场准入负责人兼首席健康经济学家、辉瑞中国公共事务及政策项目经理等职。
她目前担任的主要社会职务包括:杭州市政协海外特邀委员、上海美国商会长三角咨询委员会副主席、上海市医疗器械行业协会副会长、中国价格协会医药价格分会副会长、广东医药价格协会理事长等。她为促进中美民间经贸友好交流、推动我国医药健康产业的高质量发展而努力工作。
她拥有经济学学士、工商菅理硕士及公共卫生硕士学位,曾在中国外交学院进修高级公共外交课程。她主导并参与了多项疾病管理和健康经济学研究的设计和执行,曾为中国、日本、新加坡、印度尼西亚等国家的医疗卫生资源配置决策部门提供咨询。
Lilian Liang is Stryker China Vice President, Government Affairs & Market Access, and reports to John Collins, Stryker President, Asia Pacific. She joined Stryker China in 2019.
In the past 20 years, Lilian Liang made contributions to multinational corporations in China business strategy, market access strategy, and organizational construction and talent development. Before joining Stryker, she served as the first Vice president of Government Affairs in Greater China of Danaher Group, the first Market Access Director and Chief Health Economist in Greater China and Asia-Pacific regions of GE HealthCare, and the public affairs and project manager in Pfizer China.
Her current social positions include but not limited to: the foreign special member of Hangzhou Municipal Committee of the Chinese People's Political Consultative Conference, the executive director of the Hangzhou Public Diplomacy Association, the vice-chairman of the Yangtze River Delta Advisory Committee of the Shanghai American Chamber of Commerce, the vice-chairman of the Shanghai Medical Device Industry Association, and the vice-chairman of the Pharmaceutical Price Branch of the China Price Association. She has contributed to promoting bilateral business trade between China and the United States and promoting high quality development of healthcare industry in China.
She has a bachelor's degree in economics, a master's degree in business administration and a master's degree in public health. She has led and participated in designing and implementing multiple research projects on disease management and health economics. She has provided consultation on health resource allocation for China, Japan, Singapore, Indonesia and other countries.